Interleukin 7 Receptor Subunit Alpha (CD127 or IL7R) - Pipeline Review, H1 2016

  • ID: 3802764
  • Report
  • 59 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Cytheris SA
  • Genexine, Inc.
  • GlaxoSmithKline Plc
  • OSE Immunotherapeutics
  • Pfizer Inc.
  • MORE
Interleukin 7 Receptor Subunit Alpha (CD127 or IL7R) - Pipeline Review, H1 2016

Summary

‘ Interleukin 7 Receptor Subunit Alpha (CD127 or IL7R) - Pipeline Review, H1 2016’, provides in depth analysis on Interleukin 7 Receptor Subunit Alpha (CD127 or IL7R) targeted pipeline therapeutics.

The report provides comprehensive information on the Interleukin 7 Receptor Subunit Alpha (CD127 or IL7R), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Interleukin 7 Receptor Subunit Alpha (CD127 or IL7R) targeted therapeutics development and features dormant and discontinued projects.

The author's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from their proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Interleukin 7 Receptor Subunit Alpha (CD127 or IL7R)
- The report reviews Interleukin 7 Receptor Subunit Alpha (CD127 or IL7R) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Interleukin 7 Receptor Subunit Alpha (CD127 or IL7R) targeted therapeutics and enlists all their major and minor projects
- The report assesses Interleukin 7 Receptor Subunit Alpha (CD127 or IL7R) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Interleukin 7 Receptor Subunit Alpha (CD127 or IL7R) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Interleukin 7 Receptor Subunit Alpha (CD127 or IL7R)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Interleukin 7 Receptor Subunit Alpha (CD127 or IL7R) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Cytheris SA
  • Genexine, Inc.
  • GlaxoSmithKline Plc
  • OSE Immunotherapeutics
  • Pfizer Inc.
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Interleukin 7 Receptor Subunit Alpha (CD127 or IL7R) Overview

Therapeutics Development

Interleukin 7 Receptor Subunit Alpha (CD127 or IL7R) - Products under Development by Stage of Development

Interleukin 7 Receptor Subunit Alpha (CD127 or IL7R) - Products under Development by Therapy Area

Interleukin 7 Receptor Subunit Alpha (CD127 or IL7R) - Products under Development by Indication

Interleukin 7 Receptor Subunit Alpha (CD127 or IL7R) - Pipeline Products Glance

Late Stage Products

Early Stage Products

Interleukin 7 Receptor Subunit Alpha (CD127 or IL7R) - Products under Development by Companies

Interleukin 7 Receptor Subunit Alpha (CD127 or IL7R) - Products under Development by Universities/Institutes

Interleukin 7 Receptor Subunit Alpha (CD127 or IL7R) - Therapeutics Assessment

Assessment by Monotherapy/Combination Products

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Interleukin 7 Receptor Subunit Alpha (CD127 or IL7R) - Companies Involved in Therapeutics Development

Cytheris SA

Genexine, Inc.

GlaxoSmithKline Plc

OSE Immunotherapeutics

Pfizer Inc.

Interleukin 7 Receptor Subunit Alpha (CD127 or IL7R) - Drug Profiles

Antibody to Antagonize IL-7 Receptor Alpha for Rheumatoid Arthritis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CYT-107 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EFFI-7H - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GIFT-7 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GSK-2618960 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GX-I7 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PF-06342674 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Interleukin 7 Receptor Subunit Alpha (CD127 or IL7R) - Dormant Projects

Interleukin 7 Receptor Subunit Alpha (CD127 or IL7R) - Discontinued Products

Interleukin 7 Receptor Subunit Alpha (CD127 or IL7R) - Featured News & Press Releases

Jun 12, 2013: GSK Halts Clinical Trials Of Multiple Sclerosis Drug GSK-2618960 After Fraud Claim

Oct 24, 2012: Cytheris Announces US Orphan Drug Designation For CYT107 For Treatment Of Progressive Multifocal Leucoencephalopathy

Oct 09, 2012: Cytheris Announces Publication In Blood Demonstrating CYT107 Reverses Lymphopenia And Increases Virus Specific Immunity Post Stem Cell Transplantation

Jul 10, 2012: Cytheris Receives European Orphan Drug Designation For CYT107 For Treatment Of Progressive Multifocal Leukoencephalopathy

Mar 12, 2012: Cytheris Announces Results Of Phase II Study Indicating That Recombinant Interleukin-7 Expands CD4 T-cells In Gut Mucosa Of Chronically HIV Infected Immunological Non-responder Patients

Nov 08, 2011: Cytheris Announces Interim Results From ECLIPSE 2 Hepatitis C Multicenter Study Of IL-7 In Chronically Infected Genotype 1 And 4 Nonresponders To Standard Of Care

Oct 26, 2011: Cytheris Presents Interim Data From ECLIPSE 2 Hepatitis C Multicenter Study At AASLD Annual Meeting

May 17, 2011: Cytheris And CITN Announce Selection Of Recombinant Interleukin-7 For Initial Studies At Member Institutions

May 11, 2011: Cytheris, Lyon And ImmunID Announce Initiation Of Phase IIa Combination Trial Of IL-7 And XELODA In Metastatic Breast Cancer Treatment

Mar 01, 2011: Cytheris Announces Results From Phase IIa Study Of CYT107

Dec 07, 2010: Cytheris Announces Interim Phase I Study Results Of CYT107 In Treatment Of Post-Transplant Patients

Nov 08, 2010: Cytheris' ORVACS Phase II Clinical Study Combines Immunomodulatory Intervention And Antiretroviral Intensification To Attack Viral Reservoir Of HIV Patients

Oct 19, 2010: Cytheris Initiates ORVACS-Sponsored Phase II Clinical Study To Attack Viral Reservoir Of HIV Patients

Sep 23, 2010: Cytheris Initiates Phase II Clinical Trial Of CYT107 In Chronically Infected HIV Patients

Feb 02, 2010: Cytheris Announces Notice Of Allowance For US Patent Covering The Preparation And Uses Of Its Glycosylated Recombinant Human Interleukin-7 (CYT107)

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer 59List of Tables

Number of Products under Development for, H1 2016

Number of Products under Development by Therapy Area, H1 2016

Number of Products under Development by Indication, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Number of Products under Development by Companies, H1 2016

Products under Development by Companies, H1 2016

Number of Products under Investigation by Universities/Institutes, H1 2016

Products under Investigation by Universities/Institutes, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Stage and Mechanism of Action, H1 2016

Number of Products by Stage and Route of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016

Pipeline by Cytheris SA, H1 2016

Pipeline by Genexine, Inc., H1 2016

Pipeline by GlaxoSmithKline Plc, H1 2016

Pipeline by OSE Immunotherapeutics, H1 2016

Pipeline by Pfizer Inc., H1 2016

Dormant Projects, H1 2016

Discontinued Products, H1 2016 40List of Figures

Number of Products under Development for, H1 2016

Number of Products under Development by Therapy Area, H1 2016

Number of Products under Development by Top 10 Indication, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Mechanism of Actions, H1 2016

Number of Products by Stage and Mechanism of Actions, H1 2016

Number of Products by Routes of Administration, H1 2016

Number of Products by Stage and Routes of Administration, H1 2016

Number of Products by Molecule Types, H1 2016

Number of Products by Stage and Molecule Type, H1 2016
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • Cytheris SA
  • Genexine, Inc.
  • GlaxoSmithKline Plc
  • OSE Immunotherapeutics
  • Pfizer Inc.
  • MORE
According to the author's, recently published report 'Interleukin 7 Receptor Subunit Alpha - Pipeline Review, H1 2016'; Interleukin 7 Receptor Subunit Alpha (CD127 or IL7R) pipeline Target constitutes close to 7 molecules. Out of which approximately 5 molecules are developed by Companies and remaining by the Universities/Institutes.

Furthermore, the author says; Interleukin 7 Receptor Subunit Alpha (CD127 or IL7R) Interleukin-7 receptor is a protein found on the surface of cells. It is a receptor for interleukin-7. It acts as a receptor for thymic stromal lymphopoietin (TSLP). It plays an important role in T-cell acute lymphoblastic leukemia, multiple sclerosis, rheumatoid arthritis and juvenile idiopathic arthritis.

The report 'Interleukin 7 Receptor Subunit Alpha - Pipeline Review, H1 2016' outlays comprehensive information on the Interleukin 7 Receptor Subunit Alpha (CD127 or IL7R) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Interleukin 7 Receptor Subunit Alpha (CD127 or IL7R) targeted therapeutics development, features dormant and discontinued projects and latest news and press releases. Currently, The molecules developed by Companies in Phase II, Phase I and Preclinical stages are 1, 2 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.
Note: Product cover images may vary from those shown
5 of 5
Cytheris SA
Genexine, Inc.
GlaxoSmithKline Plc
OSE Immunotherapeutics
Pfizer Inc.
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll